secwatch.observer — SEC 8-K summary
======================================

Issuer:     Avalo Therapeutics, Inc. (AVTX)
CIK:        0001534120
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0001628280-24-045964
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avalo Q3 net income $23M; first patient dosed in Phase 2 LOTUS trial for HS
---------------------------------------------------------------------------

- Net income of $23.0M for Q3 2024 vs net loss of $5.2M in Q3 2023; diluted net loss per share $2.83.
- Cash $81.9M at Sep 30, 2024; subsequent $58.1M warrant exercise proceeds extend runway into at least 2027.
- First patient dosed in Phase 2 LOTUS trial of AVTX-009 for hidradenitis suppurativa; topline data expected 2026.
- R&D expenses $9.5M, up from $1.2M YoY due to AVTX-009 trial initiation and development costs.
- Total revenues minimal at $249K; operating loss $12.9M for the quarter.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534120/000162828024045964/0001628280-24-045964-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534120/000162828024045964/avtx-20241107.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-045964

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer